Nkarta (NKTX) Announces $150M Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Nkarta (NKTX) Surges 55% After Announcing Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
April 25, 2022 7:12 AM EDTNkarta (NASDAQ: NKTX) Surges 55% After Announcing Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
... MoreNkarta (NKTX) Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
April 25, 2022 7:03 AM EDTNkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive preliminary Phase 1 data from independent dose finding studies of its two lead chimeric antigen receptor (CAR) natural killer (NK) cell therapy candidates, NKX101 and NKX019, in two distinct groups of hematologic malignancies.
Were excited to see our CAR NK co-lead candidates, NKX101 and NKX019, show such striking early single-agent activity in heavily pretreated patient populations, with an exceptional safety profile without the side effects associated with CAR T cell therapies, said Paul J.... More
